{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:45:17Z","timestamp":1794559517389,"version":"4.9.1"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u00a0<\/jats:title>\n                  <jats:p>Nonsurgical aesthetic procedures have been steadily growing in popularity among patients of all ages and ethnicities. At present, the literature remains devoid of guidelines on optimal practices in the delivery of aesthetic medical care to patients on immunosuppressant medications. The authors of this review sought to determine the physiologic responses of immunocompromised patients related to outcomes and potential complications following nonsurgical aesthetic procedures, and to suggest recommendations for optimal management of these patients. A comprehensive systematic review of the literature was performed to identify clinical studies of patients who had undergone nonsurgical aesthetic procedures while immunosuppressed. Forty-three articles reporting on 1690 immunosuppressed patients who underwent filler injection were evaluated, of which the majority (99%; 1682\/1690) were HIV patients, while the remaining 8 were medically immunosuppressed. The complication rate of filler in this population was 28% (481\/1690), with subcutaneous nodules the most frequently reported adverse event. A detailed synthesis of complications and a review of the inflammatory responses and impact of immunosuppressants and HIV infection on filler complications is presented. The authors concluded that patients on immunomodulatory medications may be at increased risk of filler granuloma relative to the general population, while patients on immunosuppressants may be at increased risk of infectious complications. Rudimentary guidelines for optimal preprocedural patient assessment, aseptic technique, injection technique, and antibacterial and antiviral prophylaxis are reviewed. Ongoing advancements in our understanding of the mechanisms underlying these inflammatory processes will undoubtedly optimize management in this patient population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Level of Evidence: 3<\/jats:title>\n                  <jats:p\/>\n               <\/jats:sec>","DOI":"10.1093\/asj\/sjae141","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T16:33:46Z","timestamp":1720197226000},"page":"NP819-NP828","source":"Crossref","is-referenced-by-count":4,"title":["Optimal Practices in the Delivery of Aesthetic Medical Care to Patients on Immunosuppressants and Immunomodulators: A Systematic Review of the Literature"],"prefix":"10.1093","volume":"44","author":[{"given":"Leila","family":"Cattelan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Dayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina G","family":"Fabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"issue":"Supplement_2","key":"2024101511535013700_sjae141-B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/asj\/sjad354","article-title":"Aesthetic plastic surgery national databank statistics 2022","volume":"43","year":"2023","journal-title":"Aesthet Surg J"},{"issue":"12","key":"2024101511535013700_sjae141-B2","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1111\/jocd.13768","article-title":"Growth of cosmetic procedures in millennials: a 4.5-year clinical review","volume":"19","author":"Wang","year":"2020","journal-title":"J Cosmet Dermatol"},{"key":"2024101511535013700_sjae141-B3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2147\/ccid.S296970","article-title":"Characteristics of patients seeking and proceeding with non-surgical facial aesthetic procedures","volume":"14","author":"Ramirez","year":"2021","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"12","key":"2024101511535013700_sjae141-B4","doi-asserted-by":"publisher","first-page":"6976","DOI":"10.1111\/jocd.15422","article-title":"Aesthetic considerations for treating the North American multi-ethnic patient: thriving in diversity international roundtable series","volume":"21","author":"Fabi","year":"2022","journal-title":"J Cosmet Dermatol"},{"issue":"2","key":"2024101511535013700_sjae141-B5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/jocd.15516","article-title":"Aesthetic considerations when treating the Latin American patient: thriving in diversity international roundtable series","volume":"22","author":"Fabi","year":"2023","journal-title":"J Cosmet Dermatol"},{"issue":"6","key":"2024101511535013700_sjae141-B6","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1111\/jocd.15688","article-title":"Aesthetic considerations when treating patients of African descent: thriving in diversity international roundtable series","volume":"22","author":"Fabi","year":"2023","journal-title":"J Cosmet Dermatol"},{"issue":"5","key":"2024101511535013700_sjae141-B7","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1111\/jocd.15640","article-title":"Aesthetic considerations for treating the Middle Eastern patient: thriving in diversity international roundtable series","volume":"22","author":"Fabi","year":"2023","journal-title":"J Cosmet Dermatol"},{"issue":"6","key":"2024101511535013700_sjae141-B8","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1111\/jocd.15735","article-title":"Esthetic considerations for treating the patient of European descent: thriving in diversity international roundtable series","volume":"22","author":"Fabi","year":"2023","journal-title":"J Cosmet Dermatol"},{"issue":"6","key":"2024101511535013700_sjae141-B9","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1111\/jocd.15787","article-title":"Aesthetic considerations for treating the Asian patient: thriving in diversity international roundtable series","volume":"22","author":"Fabi","year":"2023","journal-title":"J Cosmet Dermatol"},{"issue":"2","key":"2024101511535013700_sjae141-B10","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2215\/cjn.08570814","article-title":"Immunosuppressive medications","volume":"11","author":"Wiseman","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2024101511535013700_sjae141-B11","doi-asserted-by":"publisher","first-page":"e14498","DOI":"10.1111\/dth.14498","article-title":"Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review","volume":"34","author":"Sadeghinia","year":"2021","journal-title":"Dermatol Ther"},{"issue":"2","key":"2024101511535013700_sjae141-B12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.21101\/cejph.a3486","article-title":"Immunosuppressive drugs in dermatology\u2013benefits and threats","volume":"58","author":"Kowal","year":"2003","journal-title":"Ann Univ Mariae Curie Sklodowska Med"},{"issue":"12","key":"2024101511535013700_sjae141-B13","doi-asserted-by":"publisher","first-page":"e26961","DOI":"10.4161\/onci.26961","article-title":"Immunosuppressants in cancer prevention and therapy","volume":"2","author":"Blagosklonny","year":"2013","journal-title":"Oncoimmunology"},{"key":"2024101511535013700_sjae141-B14","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"issue":"1","key":"2024101511535013700_sjae141-B15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000128281","article-title":"Facial cosmetic filler injections as possible target for systemic sarcoidosis in patients treated with interferon for chronic hepatitis C: two cases","volume":"217","author":"Descamps","year":"2008","journal-title":"Dermatology"},{"issue":"4","key":"2024101511535013700_sjae141-B16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/archderm.143.4.507","article-title":"Cosmetic permanent fillers for soft tissue augmentation: a new contraindication for interferon therapies","volume":"143","author":"Fischer","year":"2007","journal-title":"Arch Dermatol"},{"issue":"9","key":"2024101511535013700_sjae141-B17","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.ad.2011.01.013","article-title":"[Sarcoid granulomas in facial cosmetic filler material: induction by interferon-\u03b1 and ribavirin in a patient with hepatitis C]","volume":"102","author":"L\u00f3pez-Pesta\u00f1a","year":"2011","journal-title":"Actas Dermosifiliogr"},{"issue":"6","key":"2024101511535013700_sjae141-B18","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/bjd.14674","article-title":"Foreign body reaction triggered by cytotoxic T lymphocyte-associated protein 4 blockade 25 years after dermal filler injection","volume":"175","author":"Bisschop","year":"2016","journal-title":"Br J Dermatol"},{"issue":"6","key":"2024101511535013700_sjae141-B19","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/j.1365-2133.2012.10817.x","article-title":"Granulomatous foreign-body reaction with facial dermal fillers after omalizumab treatment for severe persistent allergic asthma: a case report","volume":"166","author":"Dammak","year":"2012","journal-title":"Br J Dermatol"},{"issue":"8","key":"2024101511535013700_sjae141-B20","doi-asserted-by":"publisher","first-page":"e228882","DOI":"10.1136\/bcr-2018-228882","article-title":"Cetuximab associated dermal filler reaction","volume":"12","author":"Pathmanathan","year":"2019","journal-title":"BMJ Case Rep"},{"issue":"4","key":"2024101511535013700_sjae141-B21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/14764172.2018.1525745","article-title":"Successful hyaluronic acid filler injection in a chronic myeloid leukemia patient taking imatinib mesylate","volume":"21","author":"Sung","year":"2019","journal-title":"J Cosmet Laser Ther"},{"issue":"3","key":"2024101511535013700_sjae141-B22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1001\/jamadermatol.2014.2494","article-title":"Multicenter prospective cohort study of the incidence of adverse events associated with cosmetic dermatologic procedures: lasers, energy devices, and injectable neurotoxins and fillers","volume":"151","author":"Alam","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"1","key":"2024101511535013700_sjae141-B23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jaad.2014.11.036","article-title":"Patient safety in procedural dermatology: part II. Safety related to cosmetic procedures","volume":"73","author":"Lolis","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2024101511535013700_sjae141-B24","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1046\/j.1524-4725.2003.29140.x","article-title":"Soft tissue augmentation with artecoll: 10-year history, indications, techniques, and complications","volume":"29","author":"Lemperle","year":"2003","journal-title":"Dermatol Surg"},{"issue":"6","key":"2024101511535013700_sjae141-B25","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1097\/PRS.0b013e31818236d7","article-title":"Foreign body granulomas after all injectable dermal fillers: part 1. Possible causes","volume":"123","author":"Lemperle","year":"2009","journal-title":"Plast Reconstr Surg"},{"issue":"6","key":"2024101511535013700_sjae141-B26","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1067\/mjd.2001.117381","article-title":"Hyaluronic acid skin fillers: adverse reactions and skin testing","volume":"45","author":"Lowe","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"4 Suppl","key":"2024101511535013700_sjae141-B27","doi-asserted-by":"publisher","first-page":"s44","DOI":"10.25251\/2.jdd.2014.13.4.s44","article-title":"Consensus recommendations on the use of injectable poly-L-lactic acid for facial and nonfacial volumization","volume":"13","author":"Vleggaar","year":"2014","journal-title":"J Drugs Dermatol"},{"issue":"12","key":"2024101511535013700_sjae141-B28","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1111\/jocd.15969","article-title":"Consensus recommendations on the use of injectable poly-l-lactic acid in Asian patients","volume":"22","author":"Avelar","year":"2023","journal-title":"J Cosmet Dermatol"},{"issue":"5","key":"2024101511535013700_sjae141-B29","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/dsu.12128","article-title":"A decade of experience with injectable poly-L-lactic acid: a focus on safety","volume":"39","author":"Bartus","year":"2013","journal-title":"Dermatol Surg"},{"issue":"16","key":"2024101511535013700_sjae141-B30","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids\u2013new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N Engl J Med"},{"issue":"5234","key":"2024101511535013700_sjae141-B31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1126\/science.270.5234.283","article-title":"Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids","volume":"270","author":"Scheinman","year":"1995","journal-title":"Science"},{"issue":"5234","key":"2024101511535013700_sjae141-B32","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1126\/science.270.5234.286","article-title":"Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis","volume":"270","author":"Auphan","year":"1995","journal-title":"Science"},{"issue":"6","key":"2024101511535013700_sjae141-B33","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/archderm.1992.01680160065005","article-title":"Tacrolimus (FK 506)\u2013a new therapeutic agent for severe recalcitrant psoriasis","volume":"128","author":"Jegasothy","year":"1992","journal-title":"Arch Dermatol"},{"issue":"1","key":"2024101511535013700_sjae141-B34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1749-6632.1993.tb17137.x","article-title":"The mechanism of action of FK-506 and cyclosporin A","volume":"696","author":"Wiederrecht","year":"1993","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"2024101511535013700_sjae141-B35","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1056\/nejm198202113060615","article-title":"Azathioprine decreases suppressor T cells in patients with multiple sclerosis","volume":"306","author":"Trotter","year":"1982","journal-title":"N Engl J Med"},{"issue":"4900","key":"2024101511535013700_sjae141-B36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1126\/science.2649979","article-title":"The purine path to chemotherapy","volume":"244","author":"Elion","year":"1989","journal-title":"Science"},{"issue":"1","key":"2024101511535013700_sjae141-B37","first-page":"18","article-title":"The emergence of mycophenolate mofetilin dermatology: from its roots in the world of organ transplantation to its versatile role in the dermatology treatment room","volume":"4","author":"Park","year":"2011","journal-title":"J Clin Aesthet Dermatol"},{"issue":"4","key":"2024101511535013700_sjae141-B38","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.semarthrit.2010.05.007","article-title":"Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus","volume":"40","author":"Sagcal-Gironella","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"2024101511535013700_sjae141-B39","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/s0889-857x(05)70358-6","article-title":"The mechanism of action of methotrexate","volume":"23","author":"Cronstein","year":"1997","journal-title":"Rheum Dis Clin North Am"},{"key":"2024101511535013700_sjae141-B40","doi-asserted-by":"publisher","first-page":"875974","DOI":"10.3389\/fmed.2022.875974","article-title":"Overview of checkpoint inhibitors mechanism of action: role of immune-related adverse events and their treatment on progression of underlying cancer","volume":"9","author":"Iranzo","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"17","key":"2024101511535013700_sjae141-B41","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1517\/14656566.2011.629187","article-title":"Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma","volume":"12","author":"Wang","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"2024101511535013700_sjae141-B42","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front Immunol"},{"issue":"2","key":"2024101511535013700_sjae141-B43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2147\/btt.s1443","article-title":"Drug focus: adalimumab in the treatment of moderate to severe psoriasis","volume":"1","author":"Vena","year":"2007","journal-title":"Biologics"},{"key":"2024101511535013700_sjae141-B44","doi-asserted-by":"publisher","first-page":"449s","DOI":"10.1016\/s0248-8663(02)00659-8","article-title":"[The interferons: pharmacology, mechanism of action, tolerance and side effects]","volume":"23 Suppl 4","author":"Arnaud","year":"2002","journal-title":"Rev Med Interne"},{"issue":"4","key":"2024101511535013700_sjae141-B45","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/j.1365-2567.2011.03412.x","article-title":"Regulation of effector and memory T-cell functions by type I interferon","volume":"132","author":"Huber","year":"2011","journal-title":"Immunology"},{"issue":"5","key":"2024101511535013700_sjae141-B46","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1055\/s-0036-1592340","article-title":"Adverse reactions to injectable fillers","volume":"32","author":"Fitzgerald","year":"2016","journal-title":"Facial Plast Surg"},{"issue":"2","key":"2024101511535013700_sjae141-B47","doi-asserted-by":"publisher","first-page":"232","DOI":"10.5999\/aps.2015.42.2.232","article-title":"Foreign body granulomas after the use of dermal fillers: pathophysiology, clinical appearance, histologic features, and treatment","volume":"42","author":"Lee","year":"2015","journal-title":"Arch Plast Surg"},{"issue":"1","key":"2024101511535013700_sjae141-B48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1479-5876-5-31","article-title":"Histamine release and fibrinogen adsorption mediate acute inflammatory responses to biomaterial implants in humans","volume":"5","author":"Zdolsek","year":"2007","journal-title":"J Transl Med"},{"issue":"2","key":"2024101511535013700_sjae141-B49","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.smim.2007.11.004","article-title":"Foreign body reaction to biomaterials","volume":"20","author":"Anderson","year":"2008","journal-title":"Semin Immunol"},{"issue":"7","key":"2024101511535013700_sjae141-B50","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1136\/jcp.36.7.723","article-title":"Granulomatous inflammation\u2013a review","volume":"36","author":"Williams","year":"1983","journal-title":"J Clin Pathol"},{"issue":"12","key":"2024101511535013700_sjae141-B51","doi-asserted-by":"publisher","first-page":"e1532","DOI":"10.1097\/gox.0000000000001532","article-title":"Late-onset inflammatory response to hyaluronic acid dermal fillers","volume":"5","author":"Bhojani-Lynch","year":"2017","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"5","key":"2024101511535013700_sjae141-B52","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nri2546","article-title":"Immunoregulatory functions of mTOR inhibition","volume":"9","author":"Thomson","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"2024101511535013700_sjae141-B53","doi-asserted-by":"publisher","first-page":"3001080","DOI":"10.1155\/2023\/3001080","article-title":"Skin cell and tissue responses to cross-linked hyaluronic acid in low-grade inflammatory conditions","volume":"2023","author":"Sanchez","year":"2023","journal-title":"Int J Inflam"},{"key":"2024101511535013700_sjae141-B54","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3389\/fimmu.2015.00231","article-title":"Hyaluronan\u2014a functional and structural sweet spot in the tissue microenvironment","volume":"6","author":"Monslow","year":"2015","journal-title":"Front Immunol"},{"issue":"2","key":"2024101511535013700_sjae141-B55","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.4049\/jimmunol.177.2.1272","article-title":"Hyaluronan fragments act as an endogenous danger signal by engaging TLR2","volume":"177","author":"Scheibner","year":"2006","journal-title":"J Immunol"},{"issue":"3","key":"2024101511535013700_sjae141-B56","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s12016-021-08859-0","article-title":"Current perspectives on severe drug eruption","volume":"61","author":"Zhang","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"2024101511535013700_sjae141-B57","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.clindermatol.2019.10.015","article-title":"The life-threatening eruptions of immune checkpoint inhibitor therapy","volume":"38","author":"Coleman","year":"2020","journal-title":"Clin Dermatol"},{"issue":"4","key":"2024101511535013700_sjae141-B58","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/cmr.0000000000000261","article-title":"Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma","volume":"26","author":"Hwang","year":"2016","journal-title":"Melanoma Res"},{"issue":"3","key":"2024101511535013700_sjae141-B59","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/cmr.0000000000000326","article-title":"Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome","volume":"27","author":"Mirza","year":"2017","journal-title":"Melanoma Res"},{"key":"2024101511535013700_sjae141-B60","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2147\/cmar.S163391","article-title":"Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"6","key":"2024101511535013700_sjae141-B61","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jaad.2015.08.040","article-title":"A systematic review of filler agents for aesthetic treatment of HIV facial lipoatrophy (FLA)","volume":"73","author":"Jagdeo","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"2024101511535013700_sjae141-B62","doi-asserted-by":"publisher","first-page":"NP170","DOI":"10.1093\/asj\/sjy226","article-title":"Late onset complications secondary to polyacrylamide hydrogel-based filler for rehabilitation of HIV-related facial lipoatropy","volume":"38","author":"Rauso","year":"2018","journal-title":"Aesthet Surg J"},{"issue":"10","key":"2024101511535013700_sjae141-B63","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1111\/dsu.12313","article-title":"Delayed-onset complications of facial soft tissue augmentation with permanent fillers in 85 patients","volume":"39","author":"Kadouch","year":"2013","journal-title":"Dermatol Surg"},{"issue":"8","key":"2024101511535013700_sjae141-B64","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1093\/asj\/sjv036","article-title":"5-year study of a polyacrylamide hydrogel-based filler for rehabilitation of HIV-related facial lipoatrophy","volume":"35","author":"Rauso","year":"2015","journal-title":"Aesthet Surg J"},{"issue":"4","key":"2024101511535013700_sjae141-B65","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1097\/PRS.0b013e3181cb4620","article-title":"Soft-tissue filler complications: the important role of biofilms","volume":"125","author":"Rohrich","year":"2010","journal-title":"Plast Reconstr Surg"},{"issue":"2","key":"2024101511535013700_sjae141-B66","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1055\/s-0036-1580734","article-title":"Etiology, prevention, and management of infectious complications of dermal fillers","volume":"30","author":"Wagner","year":"2016","journal-title":"Semin Plast Surg"},{"issue":"7","key":"2024101511535013700_sjae141-B67","doi-asserted-by":"publisher","first-page":"E59","DOI":"10.25251\/skin.4.7.2","article-title":"Delayed-onset nodules (DONs) and considering their treatment following use of hyaluronic acid (HA) fillers","volume":"14","author":"Convery","year":"2021","journal-title":"J Clin Aesthet Dermatol"},{"issue":"5","key":"2024101511535013700_sjae141-B68","doi-asserted-by":"publisher","first-page":"571","DOI":"10.36849\/JDD.2014.13.5.571","article-title":"Effect of prophylactic antibiotics on polyacrylamide gel safety in facial augmentation","volume":"13","author":"Nygart","year":"2014","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"2024101511535013700_sjae141-B69","first-page":"E5","article-title":"Prophylaxis and treatment of herpetic infections","volume":"10","author":"King","year":"2017","journal-title":"J Clin Aesthet Dermatol"},{"key":"2024101511535013700_sjae141-B70"},{"issue":"1","key":"2024101511535013700_sjae141-B71","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5999\/aps.2021.00766","article-title":"Immunogenicity of botulinum toxin","volume":"49","author":"Wee","year":"2022","journal-title":"Arch Plast Surg"},{"issue":"13","key":"2024101511535013700_sjae141-B72","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1002\/mds.23254","article-title":"Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX\u00ae) across multiple indications","volume":"25","author":"Naumann","year":"2010","journal-title":"Mov Disord"}],"container-title":["Aesthetic Surgery Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjae141\/58800472\/sjae141.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/44\/11\/NP819\/59758715\/sjae141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/44\/11\/NP819\/59758715\/sjae141.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T11:54:00Z","timestamp":1728993240000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asj\/article\/44\/11\/NP819\/7706467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":72,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,7,5]]},"published-print":{"date-parts":[[2024,10,15]]}},"URL":"https:\/\/doi.org\/10.1093\/asj\/sjae141","relation":{},"ISSN":["1090-820X","1527-330X"],"issn-type":[{"value":"1090-820X","type":"print"},{"value":"1527-330X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,7,5]]}}}